These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37563039)

  • 1. How to save a life: Public awareness of a national mass media take home naloxone campaign, and effects of exposure to campaign components on overdose knowledge and responses.
    Sumnall HR; Atkinson AM; Anderson M; McAuley A; Trayner K
    Int J Drug Policy; 2024 Sep; 131():104111. PubMed ID: 37563039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National increase in the community supply of take-home naloxone associated with a mass media campaign in Scotland: a segmented time series analysis.
    Trayner K; Yeung A; Sumnall HR; Anderson M; Glancy ME; Atkinson A; Smith M; McAuley A
    Int J Drug Policy; 2024 Sep; 131():104106. PubMed ID: 37563038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design details for overdose education and take-home naloxone kits: Codesign with family medicine, emergency department, addictions medicine and community.
    Sellen K; Goso N; Halleran L; Mulvale-Fletcher A; Sarmiento F; Ligabue F; Handford C; Klaiman M; Milos G; Wright A; Charles M; Sniderman R; Hunt R; Parsons JA; Leece P; Hopkins S; Shahin R; Jüni P; Morrison L; Campbell DM; Strike C; Orkin A;
    Health Expect; 2022 Oct; 25(5):2440-2452. PubMed ID: 35909312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for Take-home naloxone In Multicentre Emergency (TIME) settings: feasibility study.
    Jones M; Bell F; Benger J; Black S; Buykx P; Dixon S; Driscoll T; Evans B; Edwards A; Fuller G; Goodacre S; Hoskins R; Hughes J; John A; Jones J; Moore C; Sampson F; Watkins A; Snooks H
    Pilot Feasibility Stud; 2020; 6():96. PubMed ID: 32670598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Awareness, Possession, and Use of Take-Home Naloxone Among Illicit Drug Users, Vancouver, British Columbia, 2014-2015.
    Nolan S; Buxton J; Dobrer S; Dong H; Hayashi K; Milloy MJ; Kerr T; Montaner J; Wood E
    Public Health Rep; 2017; 132(5):563-569. PubMed ID: 28750193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs.
    Sajwani HS; Williams AV
    Harm Reduct J; 2022 Oct; 19(1):117. PubMed ID: 36266701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation.
    McDonald R; Campbell ND; Strang J
    Drug Alcohol Depend; 2017 Sep; 178():176-187. PubMed ID: 28654870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overdose and take-home naloxone in emergency settings: A pilot study examining feasibility of delivering brief interventions addressing overdose prevention with 'take-home naloxone' in emergency departments.
    Black E; Monds LA; Chan B; Brett J; Hutton JE; Acheson L; Penm J; Harding S; Strumpman D; Demirkol A; Lintzeris N
    Emerg Med Australas; 2022 Aug; 34(4):509-518. PubMed ID: 35021268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study protocol for a European, mixed methods, prospective, cohort study of the effectiveness of naloxone administration by community members, in reversing opioid overdose: NalPORS.
    Metrebian N; Carter B; Eide D; McDonald R; Neale J; Parkin S; Dascal T; Mackie C; Day E; Guterstam J; Horsburgh K; Kåberg M; Kelleher M; Smith J; Thiesen H; Strang J
    BMC Public Health; 2023 Aug; 23(1):1608. PubMed ID: 37612698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives.
    Lintzeris N; Monds LA; Bravo M; Read P; Harrod ME; Gilliver R; Wood W; Nielsen S; Dietze PM; Lenton S; Shanahan M; Jauncey M; Jefferies M; Hazelwood S; Dunlop AJ; Greenaway M; Haber P; Ezard N; Malcom A
    Drug Alcohol Rev; 2020 Jan; 39(1):55-65. PubMed ID: 31774221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does Digital Video Advertising Increase Population-Level Reach of Multimedia Campaigns? Evidence From the 2013 Tips From Former Smokers Campaign.
    Davis KC; Shafer PR; Rodes R; Kim A; Hansen H; Patel D; Coln C; Beistle D
    J Med Internet Res; 2016 Sep; 18(9):e235. PubMed ID: 27627853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoting public awareness of randomised clinical trials using the media: the 'Get Randomised' campaign.
    Mackenzie IS; Wei L; Rutherford D; Findlay EA; Saywood W; Campbell MK; Macdonald TM
    Br J Clin Pharmacol; 2010 Feb; 69(2):128-35. PubMed ID: 20233175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "It can save your life, that's all I know," barriers and facilitators for engagement in take-home naloxone for people receiving opioid substitution treatment in regional Australia: An explorative study.
    Natale I; Harvey C; Wood P; Anderson K
    Qual Res Med Healthc; 2023 Jul; 7(2):10868. PubMed ID: 37692452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons learned from ramping up a Canadian Take Home Naloxone programme during a public health emergency: a mixed-methods study.
    Young S; Williams S; Otterstatter M; Lee J; Buxton J
    BMJ Open; 2019 Oct; 9(10):e030046. PubMed ID: 31662368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addiction stigma and the production of impediments to take-home naloxone uptake.
    Fomiatti R; Farrugia A; Fraser S; Dwyer R; Neale J; Strang J
    Health (London); 2022 Mar; 26(2):139-161. PubMed ID: 32529843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review.
    Moustaqim-Barrette A; Dhillon D; Ng J; Sundvick K; Ali F; Elton-Marshall T; Leece P; Rittenbach K; Ferguson M; Buxton JA
    BMC Public Health; 2021 Mar; 21(1):597. PubMed ID: 33771150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Naloxone? Not for me!" First cross-assessment by patients and healthcare professionals of the risk of opioid overdose.
    Aquizerate A; Rousselet M; Cochard A; Guerlais M; Gerardin M; Lefebvre E; Duval M; Laforgue EJ; Victorri-Vigneau C
    Harm Reduct J; 2024 Jan; 21(1):20. PubMed ID: 38263159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does training people to administer take-home naloxone increase their knowledge? Evidence from Australian programs.
    Dietze PM; Draper B; Olsen A; Chronister KJ; van Beek I; Lintzeris N; Dwyer R; Nelson M; Lenton S
    Drug Alcohol Rev; 2018 May; 37(4):472-479. PubMed ID: 29473245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Death matters: understanding heroin/opiate overdose risk and testing potential to prevent deaths.
    Strang J
    Addiction; 2015 Jul; 110 Suppl 2():27-35. PubMed ID: 26042565
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.